H-E-B recalled 300,000 units of inControl Sterile Alcohol Pads on July 7, 2025. The recall follows reports that isopropyl alcohol levels fall below the labeled concentration. Consumers should stop using the product immediately.
Subpotent Drug- isopropyl alcohol levels fall below the labeled concentration.
Consumers and healthcare providers should stop using this product immediately. Contact MEDLINE INDUSTRIES, LP - Northfield or your healthcare provider for guidance. Notification method: Letter
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
The recalled product is inControl Sterile Alcohol Pads, packaged in boxes of 100. The affected product has the NDC number 37808-809-09 and was distributed nationwide.
The alcohol pads are subpotent, meaning they do not contain the labeled concentration of isopropyl alcohol. This could lead to ineffective disinfection, posing a risk of infection.
No specific injuries or incidents have been reported to date regarding this product. The recall is precautionary due to the subpotent nature of the drug.
Consumers should stop using the alcohol pads immediately. Contact Medline Industries at the provided contact for guidance and potential refund options.
For further information, contact Medline Industries, LP at 1-800-633-5463 or visit the FDA recall page at https://www.accessdata.fda.gov/scripts/enforcement/enforce_rpt-Product-Tabs.cfm?recall_number=D-0603-2025.
Get instant alerts for recalls that affect you. Free forever.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.
Fresenius Kabi Compounding recalled 1,578 bags of vancomycin HCl injection on February 5, 2026. The company cited a lack of assurance of sterility as the reason for the recall. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,410 bags of ketamine HCl injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers and consumers must stop using this product immediately.
Fresenius Kabi Compounding recalled 10,548 bags of thiamine HCl injection on February 5, 2026. The recall follows a lack of assurance of sterility, posing a high health risk. Affected products include several lots expiring between February and May 2026.
Pro Numb Tattoo Numbing Spray was recalled due to cGMP deviations. The recall affects products distributed nationwide in the USA. Consumers should stop using the spray immediately and contact Pro Numb Tattoo Numbing Spray LLC for guidance.
Pro Numb Tattoo Numbing Spray was recalled on February 2, 2026 due to cGMP deviations. The product, containing 4% lidocaine, is distributed by Pro Numb Tattoo Numbing Spray LLC. Consumers should stop using it immediately and contact the company for further guidance.